In addition, the inhibition of poly (ADP-ribose) polymerase-1 (PARP), has shown anti-tumour effects with a strong synergism and good tolerance in combination with anti-HER2 targeted therapy or ET in vitro and in phase I/II trials independently of DNA repair deficiency.30 This evidence concerns the gene PARP1 and neoplasm.